Orchard Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Orchard Capital Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-121,020	Closed	-$6.5M	–	54
2022 Q3	$6.5M	Hold	121,020	–	–	2.43%	19
2022 Q2	$6.94M	Buy	121,020 +3,046	+3%	+$173K	2.17%	24
2022 Q1	$8.28M	Buy	117,974 +8,015	+7%	+$582K	2.35%	19
2021 Q4	$10.6M	Buy	109,959 +2,084	+2%	+$193K	3.11%	15
2021 Q3	$9.38M	Hold	107,875	–	–	2.82%	16
2021 Q2	$8.83M	Buy	107,875 +3,391	+3%	+$282K	2.55%	18
2021 Q1	$9.94M	Buy	104,484 +10,034	+11%	+$949K	3.13%	14
2020 Q4	$5.86M	Buy	+94,450	New	+$5.38M	2.5%	22

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Orchard Capital Management's LGND Position: Q4 2022 in Review

Orchard Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q4 2022, closing a stake of 121,020 shares — an estimated $6.5M sold.

Orchard Capital Management first reported a position in LGND in Q4 2020 and held it in 8 quarters. The position peaked at $10.6M in Q4 2021. 198 funds tracked by Wall St. Rank hold LGND as of Q4 2022.

Orchard Capital Management reported no remaining Ligand Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Orchard Capital Management sold 121,020 Ligand Pharmaceuticals shares in Q4 2022, an estimated $6.5M.
Orchard Capital Management first reported a position in Ligand Pharmaceuticals in Q4 2020 and held it in 8 quarters.
Orchard Capital Management's Ligand Pharmaceuticals position peaked at $10.6M in Q4 2021.
198 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2022.

Based on Orchard Capital Management's 13F filing for Q4 2022, filed 10 Feb 2023.